Outcomes Associated With Use of a Kinin B2 Receptor Antagonist Among Patients With COVID-19
- PMID: 32789513
- PMCID: PMC7426743
- DOI: 10.1001/jamanetworkopen.2020.17708
Outcomes Associated With Use of a Kinin B2 Receptor Antagonist Among Patients With COVID-19
Abstract
This case-control study examines the association between receipt of the bradykinin 2 (B2) receptor antagonist icatibant and improved oxygenation in patients with coronavirus disease 2019 (COVID-19).
Conflict of interest statement
Figures
References
-
- Assessment Report EPAR. 09-020-2018. Accessed April 2, 2020. https://www.ema.europa.eu/en/medicines/human/EPAR/firazyr
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources